Introgen to Present ADVEXIN Phase 3 Study Results at Cancer Clinical Trials and Personalized Medicine Conference
News Jul 21, 2008
Introgen Therapeutics, Inc. has announced that the company will present the results from its recently completed Phase 3 trial of ADVEXIN in recurrent head and neck cancer at the American Association for Cancer Research (AACR) Centennial Conference on Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine.
The conference will be held July 20-23, 2008 at the Hyatt Regency Monterey in Monterey, CA.
Introgen’s presentation will review the previously announced findings from the Company’s Phase 3 trial which demonstrated that ADVEXIN successfully achieved its primary and secondary efficacy endpoints in the study’s pre-specified p53 biomarker population.
In addition, Introgen will present supplemental statistical analyses that are included in the Company’s Biologics License Application and Marketing Authorization Application in the U.S. and Europe, respectively.
Scientists from the UNC School of Medicine discovered that the anti-inflammatory protein NLRP12 normally helps protect mice against obesity and insulin resistance when they are fed a high-fat diet. The researchers also reported that the NLRP12 gene is underactive in people who are obese, making it a potential therapeutic target for treating obesity and diabetes.READ MORE